India to Remain a Cost-Competitive Hub

Contract manufacturing of active pharmaceutical ingredients (APIs) and finished dosage drug forms will grow in India at 30%-40%/year until 2013, says a new report from Frost & Sullivan India (F&S; Kolkata). The cost of manufacturing in India is increasing, but the country continues to be a leading destination for outsourcing pharma manufacturing, F&S says. “India has already emerged as one of the most preferred outsourcing hubs for many global players including big pharmaceutical companies, and we can expect more than 30% growth in the contract...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers